<DOC>
	<DOC>NCT00656643</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation at various doses in patients with diabetic macular edema.</brief_summary>
	<brief_title>Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion Criteria include but are not limited to: Diagnosed with diabetes mellitus Macular edema secondary to diabetic retinopathy Visual acuity of 20/40 to 20/200 in study eye Exclusion Criteria include but are not limited to: Any other ocular disease that could compromise vision in the study eye Any of the following treatments to the study eye within 90 days prior to study start: intravitreal injections; posterior subtenons steroids; focal/grid macular photocoagulation; intraocular surgery Capsulotomy of the study eye within 30 days prior to study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>